Take a look at some of Friday's midday movers:
Target moved lower after the retailer cut its fourth-quarter earnings forecast because of the massive credit-card breach it suffered. It said up to 110 million customers were affected. According to New York Attorney General Eric Schneiderman, state attorneys general from around the country are banding together to probe the data breach.
CGI Group moved lower on a Washington Post report that the Obama administration will end its contract with the company, to be replaced by Accenture.
Homebuilders Lennar, KB Home, PulteGroup, D.R. Horton and Toll Brothers moved higher as yields moved lower on the weak December employment report.
Gold miners Newmont Mining, Barrick Gold , Goldcorp, and AngloGold Ashanti also climbed as gold prices rose on the weak December employment report.
YRC Worldwide fell as the company called off a meeting with bankers after the Teamsters rejected the company's proposition to extend cuts in pay and overtime.
Blackberry rose as RBC Capital upgraded the company to sector perform from underperform with a price target of $10 a share.
Micron Technology moved higher as Argus begins coverage with a buy rating with a price target of $31 a share.
Pfizer fell after Cowen downgraded the stock to market perform from outperform.
Conatus Pharmaceuticals gained ground on the back of ' spectacular gains. The company is focused on the treatment of liver disease.
fell after its treatment for a rare type of low blood pressure was not well received by the FDA.
moved higher on a report the automaker sold more cars in China than for the first time in nine years.
moved higher on news it was being acquired by investment funds managed by H.I.G. Capital for $392 million, or $46.50 a share.
gained ground as it sees strong gross margins in fiscal year 2013.
rose as its guided fourth-quarter earnings to the high-end of its outlook.
moved higher after Maxim Group upgraded the stock to buy from hold with a $200 a share price target.
climbed on news its launching a number of clinical trials to treat ovarian cancer.
(Read More: )
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at marketinsider@cnbc.com